Total amount: € 0,00
Chiosi F. 1, Paoletta M. 1, Boemio G. 1, Pascotto A. 1, Di Iorio R. 2, Verolino M. 3, Filippelli M. 2, Costagliola C. 2
1 Dipartimento di Oftalmologia Seconda Università degli Studi di Napoli Napoli, Italia;
2 Dipartimento di Scienze per la Salute Università degli Studi del Molise Campobasso, Italia;
3 Dipartimento di Oftalmologia Ospedale Boscotrecase, Napoli, Italia
Aim: To report the morphologic and functional outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen®) in patients with myopic choroidal neovascularization.
Methods: An open-label, non-randomized, prospective clinical trial was performed. Morphologic outcome (FT) was assessed by optical coherence tomography, whereas functional outcomes were best-corrected visual acuity (BCVA) and microperimetry (MP). Treatment protocol consisted of 3 consecutive injections of pegaptanib (IVP; 0.3 mg/ 0.05 mL; baseline, 6th week and 12th week). Follow-up checks were scheduled at the following intervals: baseline, 18- and 24- weeks.
Results: Ten eyes from 10 patients were studied. All patients completed follow-up at 24 weeks. After IOVP a signficante decerase of FT (-22%) and at the end of follow-up, CNV closure was obtained in all eyes. An improvement of functional parameters was recorded in all patients (BCVA from 25.5±8.09 letters to 45.5±8.16 letters, P<0.0001; MP from 8.40±2.14 dB to 10.6±2.05 dB, P<0.01). The mean number of IVP was 3 and none of patients met the retreatment criterion during the entire follow-up period. Neither ocular nor systemic side effects were observed.
Conclusion: Our findings demonstrate that the selective inhibition of VEGF-165 isoform by IVP is an effective treatment for mCNV.